Table 3.
Group number | Group name | Number of mice | Brain weight (g) | Neuron counts (×106 cells) | MSN cross-sectional area (μm2) |
---|---|---|---|---|---|
1 | WT-Ctrl | 9 (5F, 4M) | 0.508 ± 0.025 | 1.264 ± 0.035 | 85.75 ± 2.33 |
2 | WT-DOPA | 7 (5F, 2M) | 0.501 ± 0.020 | 1.225 ± 0.016 | 87.51 ± 1.98 |
3 | WT- DOPA/TBZ | 8 (5F, 3M) | 0.501 ± 0.019 | 1.258 ± 0.020 | 91.34 ± 2.57 |
4 | YAC-Ctrl | 9 (4F, 5M) | 0.432 ± 0.007 | 1.090 ± 0.020 | 71.99 ± 1.48 |
5 | YAC-DOPA | 8 (4F, 4M) | 0.423 ± 0.008 | 1.014 ± 0.028 | 75.53 ± 1.16 |
6 | YAC- DOPA/TBZ | 7 (4F, 3M) | 0.464 ± 0.010 | 1.182 ± 0.026 | 77.21 ± 1.15 |
The average brain weight, striatal neuronal counts, and striatal neuron cross-sectional area were measured in 11-month-old WT and YAC128 mice at the conclusion of the L-DOPA/TBZ trial. Several mice died during the behavioral stage of the trial and were not used in neuropathological analysis. The data are shown as mean ±SEM.